Align Technology stock holds firm as investors await fresh numbers

Align Technology (US0162551016) remains a closely watched name after its latest reported figures showed the scale of the business and the pressure points that matter most for the share price. The company reported fiscal 2025 revenue of $3.98 billion, up 1.0% from $3.94 billion in 2024, while full-year operating margin reached 14.2%.

Revenue and margin set the tone

The company said Invisalign revenue and iTero scanner demand continue to define the investment case, with product mix and doctor adoption still central to the trajectory. In fiscal 2025, clear aligner volume and scanner utilization remained the key operating metrics behind the reported $3.98 billion in sales.

That revenue base matters because even modest changes in volume can move profitability quickly in a high-margin consumables and systems model. A 1.0% year-over-year increase in 2025 is not a breakout, but it does show that the business did not lose scale in a year when the market has been focused on orthodontic spending and reimbursement sensitivity.

2025 numbers still matter

Fiscal 2025 net income was $519.4 million, compared with $486.1 million in 2024, and diluted EPS rose to $6.89 from $6.30. Those figures give investors a cleaner read than headline revenue alone because they show the company converting a near-flat sales year into higher profit and earnings per share.

The margin and EPS combination is the key comparison here. Revenue rose just 1.0% year over year, but net income increased 6.8% and EPS advanced 9.4%, which points to operating leverage and disciplined cost control rather than top-line acceleration.

Chart focus near the latest level

For market context, Align Technology stock traded around $130.20 on the latest available market quote used here, a level that frames how investors are discounting the company against its 2025 earnings base. The stock is being judged less on a broad growth story and more on whether future quarters can turn that $3.98 billion revenue base into a clearer expansion trend.

In that setting, the most relevant comparison is not a slogan about demand but the gap between slow revenue growth and faster earnings growth. That spread is what can keep the stock supported if the market believes the company can sustain margins while unit demand rebuilds.

Invisalign remains central

Invisalign is still the product line that carries the most investor attention because it links Align Technology directly to orthodontic treatment adoption. The company’s business still depends on how consistently aligner demand converts into shipments, doctor activity, and repeat case starts across its installed base.

iTero remains the other important lever because scanner adoption can reinforce the broader workflow around aligners and treatment planning. Taken together, the two franchises explain why the market continues to read every revenue, margin, and EPS update as a signal about the durability of the model.

Stock level and context

At $130.20 as of the latest market quote, Align Technology stock is being valued against fiscal 2025 revenue of $3.98 billion, net income of $519.4 million, and diluted EPS of $6.89. Those are the numbers that now matter most for the next reset in expectations.

What stands out is the combination of only 1.0% revenue growth and a 9.4% EPS increase in fiscal 2025. That gap is the clearest evidence that the company is still making the market focus on profitability rather than on rapid expansion.